We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Events

05 Aug 2026 - 07 Aug 2026
18 Aug 2026 - 20 Aug 2026

BD to Supply Molecular Platform to BioReference

By HospiMedica staff writers
Posted on 07 Jul 2006
BD Diagnostics, a segment of Becton, Dickinson and Company (BD, Franklin Lakes, NJ; USA), has signed an agreement with BioReference Laboratories (BLRI, Elmwood Park, NJ, USA) whereby BD will supply BLRI with instrumentation and reagents for testing sexually transmitted infections (STIs).

Under the agreement, testing for Chlamydia trachomatis and Neisseria gonorrhoeae will be run on the Scara robotic automation platform of the BD Viper system. More...
BD will be the primary supplier to BioReference for testing these two diseases.

The BD Viper system incorporates a Scara robot that delivers robust performance by eliminating all pumps, syringes, and tubing that were a major weakness of earlier-generation molecular automation. The isothermal, real-time amplification and detection offered by BD's strand displacement amplification (SDA) has greatly simplified complex molecular testing and made this technology more accessible to clinical laboratories.

Early and accurate diagnosis of sexually transmitted infections, specifically chlamydia and gonorrhea, leads to more timely and effective treatment, reduces the potential for further spread of infection, and helps insure better patient outcomes. Left untreated in women, chlamydia can lead to infertility, ectopic pregnancy, and debilitating pelvic pain.

BD is a medical technology company that makes and sells medical devices, instrument systems, and reagents. The company is focused on enhancing the quality and speed of diagnosing infectious diseases, improving drug therapy, advancing research, and the discovery of new drugs and vaccines. It serves healthcare institutions, life science researchers, clinical laboratories, industry, and the general public.



Related Links:
Becton, Dickinson and Company
BioReference Laboratories

Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Biochip Array Technology
Evidence MultiSTAT Drugs of Abuse Urine Multiplex Panel
Immobilization System
Cranial 4Pi Immobilization
Medical Adhesive
MED 5570U
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Critical Care

view channel
Image Credit: 123RF

Existing Cardiovascular Risk Calculators Predict Several Common Cancers

Cardiovascular risk calculators are embedded in primary and secondary care to estimate 10‑year risk of heart attack or stroke from factors such as age, body mass index, and smoking. Many of these same... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.